Compounds > 14-o-phosphonooxymethyltriptolide
Page last updated: 2024-11-13

14-o-phosphonooxymethyltriptolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 14-O-Phosphonooxymethyltriptolide (14-OPT)

**What is it?**

14-OPT is a **synthetic derivative** of the naturally occurring compound **triptolide**, which is extracted from the Chinese herb **Tripterygium wilfordii**. It's a potent **immunosuppressant** with potential therapeutic applications in various fields.

**Key Characteristics:**

* **Chemical Structure:** 14-OPT differs from triptolide by having a phosphonooxymethyl group attached at the 14-position of the triptolide molecule.
* **Improved Properties:** This structural modification enhances its **pharmacokinetic properties** (how the body absorbs, distributes, metabolizes, and eliminates the drug), leading to improved **bioavailability**, **stability**, and **therapeutic index** compared to triptolide.

**Why is it important for research?**

14-OPT is of significant interest to researchers due to its promising potential in various areas, including:

**1. Treatment of Autoimmune Diseases:**

* **Mechanism of Action:** 14-OPT effectively **suppresses the immune system** by inhibiting the activity of various immune cells, including T cells, B cells, and macrophages. This makes it a potential candidate for treating autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis.
* **Clinical Trials:** Several clinical trials are underway to evaluate the efficacy and safety of 14-OPT in treating different autoimmune diseases.

**2. Cancer Therapy:**

* **Anti-Cancer Effects:** 14-OPT exhibits anti-proliferative effects on various cancer cell lines, potentially through inhibiting cell growth, inducing apoptosis, and blocking angiogenesis.
* **Preclinical Studies:** Extensive research is ongoing to investigate its potential as a cancer treatment, focusing on both solid and hematologic malignancies.

**3. Other Potential Applications:**

* **Organ Transplantation:** 14-OPT's immunosuppressive properties make it a potential candidate for preventing rejection after organ transplantation.
* **Inflammatory Diseases:** Its anti-inflammatory effects could be beneficial in treating chronic inflammatory diseases like inflammatory bowel disease.

**Current Research Focus:**

Ongoing research focuses on:

* **Optimizing 14-OPT's delivery methods** to improve its therapeutic effectiveness.
* **Developing new drug formulations** to minimize its side effects.
* **Understanding its precise mechanisms of action** to further explore its therapeutic potential.

**Overall, 14-OPT holds immense promise as a potential treatment for various diseases. Its unique properties and favorable pharmacokinetic profile make it a valuable target for future research and development.**

14-O-phosphonooxymethyltriptolide disodium salt: pro-drug of triptolide; has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46203139
CHEMBL ID3740500
MeSH IDM0582247

Synonyms (10)

Synonym
minnelide
CHEMBL3740500
trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-((phosphonooxy)methoxy)-, sodium salt (1:2), (3bs,4as,5ar,6r,6as,7as,7bs,8as,8bs)-
1254702-87-8
14-o-phosphonooxymethyltriptolide disodium salt
1CIV2UMO40 ,
unii-1civ2umo40
disodium;[(1s,2s,4s,5s,7s,8r,9r,11s,13s)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl]oxymethyl phosphate
Q27252236
F82363

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, this study aimed to investigate whether minnelide, combined with Angptl3 knockout, could completely protect mice with AN and its mechanism."( Minnelide combined with Angptl3 knockout completely protects mice with adriamycin nephropathy via suppression of TGF-β1-Smad2 and p53 pathways.
Ji, B; Liu, J; Ma, Y; Shen, Q; Xu, H; Yin, Y; Yu, J, 2023)		0.91
" Therefore, the present study aimed to investigate whether minnelide combined with mAb could further protect mice with AN and the underlying mechanisms."( Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis.
Ji, B; Liu, J; Shen, Q; Xu, H; Yin, Y; Yu, J, 2023)		0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID1265938Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as mortality at 0.6 to 0.9 mg/kg, po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265906Stability of the compound in simulated intestinal fluid assessed as compound remaining at pH 7.5 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265892Chemical stability of the compound in buffer assessed as compound remaining at pH 7.4 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265937Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as morbidity at 0.6 to 0.9 mg/kg, po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265907Stability of the compound in simulated intestinal fluid assessed as compound remaining at pH 7.5 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265879Chemical stability of the compound in buffer assessed as compound remaining at pH 4 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265893Chemical stability of the compound in buffer assessed as compound remaining at pH 9 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265903Stability of the compound in simulated intestinal fluid assessed as compound remaining at pH 7.5 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265935Prodrug conversion in glycine buffer assessed as bovine intestinal mucosal alkaline phosphatase-mediated triptolide and formaldehyde formation at pH 9.82015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265913Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 4 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265899Stability of the compound in simulated gastric fluid assessed as compound remaining at pH 7.5 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265902Stability of the compound in simulated gastric fluid assessed as compound remaining at pH 7.5 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265878Chemical stability of the compound in buffer assessed as compound remaining at pH 4 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265908Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 40 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265905Stability of the compound in simulated intestinal fluid assessed as compound remaining at pH 7.5 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265891Chemical stability of the compound in buffer assessed as compound remaining at pH 7.4 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265897Chemical stability of the compound in buffer assessed as compound remaining at pH 9 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265923Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as mortality at 0.9 mg/kg, ip administered for 4 weeks2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265898Stability of the compound in simulated gastric fluid assessed as compound remaining at pH 7.5 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265904Stability of the compound in simulated intestinal fluid assessed as compound remaining at pH 7.5 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265924Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as mortality at 0.9 mg/kg, ip administered for 2 weeks2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265888Chemical stability of the compound in buffer assessed as compound remaining at pH 7.4 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265926Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as weight gain at 0.9 mg/kg, ip administered 14 days measured post last dose2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265927Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as skin irritation at 0.9 mg/kg, ip administered 14 days measured post last dose2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265920Antitumor activity against human HT-29 cells xenografted in athymic nude mouse at 0.3 to 0.9 mg/kg, ip qd administered for 28 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265894Chemical stability of the compound in buffer assessed as compound remaining at pH 9 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265880Chemical stability of the compound in buffer assessed as compound remaining at pH 4 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265889Chemical stability of the compound in buffer assessed as compound remaining at pH 7.4 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265882Chemical stability of the compound in buffer assessed as compound remaining at pH 4 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265874Chemical stability of the compound in buffer assessed as compound remaining at pH 2 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265869Chemical stability of the compound in buffer assessed as compound remaining at pH 1 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265925Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as mortality at 0.9 mg/kg, ip administered for 2 weeks followed by 3 times per week2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265886Chemical stability of the compound in buffer assessed as compound remaining at pH 6 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265915Half life of the compound in buffer at 4 degC at pH 7.42015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265871Chemical stability of the compound in buffer assessed as compound remaining at pH 1 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265867Second dissociation constant, pKa2 of the compound by 31P NMR analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265896Chemical stability of the compound in buffer assessed as compound remaining at pH 9 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265872Chemical stability of the compound in buffer assessed as compound remaining at pH 1 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265890Chemical stability of the compound in buffer assessed as compound remaining at pH 7.4 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265868Chemical stability of the compound in buffer assessed as compound remaining at pH 1 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265881Chemical stability of the compound in buffer assessed as compound remaining at pH 4 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265901Stability of the compound in simulated gastric fluid assessed as compound remaining at pH 7.5 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265932Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as moribund condition at 1.2 mg/kg, po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265914Half life of the compound in buffer at 25 degC at pH 7.42015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265910Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 60 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265870Chemical stability of the compound in buffer assessed as compound remaining at pH 1 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265916Shelf life of the compound in buffer assessed as time for 10% loss of compound at 25 degC at pH 7.42015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265873Chemical stability of the compound in buffer assessed as compound remaining at pH 2 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265900Stability of the compound in simulated gastric fluid assessed as compound remaining at pH 7.5 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265912Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 25 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1424479Stability assessed as shelf life at 4 degC2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1265929Antitumor activity against human A2780 cells xenografted in athymic nude mouse at 0.6 to 0.9 mg/kg, ip and po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265928Toxicity in athymic nude mouse xenografted with human HT-29 cells assessed as necrosis at 0.9 mg/kg, ip administered 14 days measured post last dose2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265922Antitumor activity against human HT-29 cells xenografted in athymic nude mouse at 0.9 mg/kg, ip qd administered for 2 weeks followed by 3 times per week2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265909Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 50 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265887Chemical stability of the compound in buffer assessed as compound remaining at pH 6 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265919Stability of the compound in glycine buffer at pH 9.8 after 1 hr in absence of bovine intestinal mucosal alkaline phosphatase2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265911Chemical stability of the compound in buffer assessed as pseudo-first-order rate constant at 70 degC at pH 7.4 by Arrhenius plot analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265931Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as dehydration at 1.2 mg/kg, po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265917Shelf life of the compound in buffer assessed as time for 10% loss of compound at 4 degC at pH 7.42015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265930Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as anorexia at 1.2 mg/kg, po administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265884Chemical stability of the compound in buffer assessed as compound remaining at pH 6 after 2 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265883Chemical stability of the compound in buffer assessed as compound remaining at pH 6 after 1 hr by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1555818Half life of the compound2019European journal of medicinal chemistry, Aug-15, Volume: 176Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1265895Chemical stability of the compound in buffer assessed as compound remaining at pH 9 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265885Chemical stability of the compound in buffer assessed as compound remaining at pH 6 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1555819Aqueous solubility of the compound2019European journal of medicinal chemistry, Aug-15, Volume: 176Triptolide: Medicinal chemistry, chemical biology and clinical progress.
AID1265918Half life of the compound in glycine buffer assessed as bovine intestinal mucosal alkaline phosphatase-mediated compound degradation at pH 9.82015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265933Toxicity in athymic nude mouse xenografted with human A2780 cells assessed as survival at 0.6 to 0.9 mg/kg, ip administered for 30 days2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1424478Solubility of the compound2017European journal of medicinal chemistry, Dec-15, Volume: 142From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.
AID1265921Antitumor activity against human HT-29 cells xenografted in athymic nude mouse at 0.9 mg/kg, ip qd administered for 4 weeks2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265877Chemical stability of the compound in buffer assessed as compound remaining at pH 2 after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265876Chemical stability of the compound in buffer assessed as compound remaining at pH 2 after 8 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1265875Chemical stability of the compound in buffer assessed as compound remaining at pH 2 after 4 hrs by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
AID1707230Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1265866Aqueous solubility of the compound in Tris buffer at pH 7.4 at room temperature by HPLC analysis2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's28 (84.85)24.3611
2020's5 (15.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.03 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (15.15%)6.00%
Case Studies1 (3.03%)4.05%
Observational0 (0.00%)0.25%
Other27 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.1110aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
melatonin
[no description available]		3.2510acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.110pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		3.2510aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.1510delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.5820taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
irinotecan
[no description available]		2.1510carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
triptonide
triptonide: extracted from Tripterygium wilfordii; structure given in first source. triptonide : A diterpene triepoxide that is triptobenzene K in which the acylhydroquinone moiety has undergone oxidation to the corresponding triepoxyketone derivative. It has been isolated from the roots of Tripterygium wilfordii.		2.2510butenolide;
cyclic ketone;
diterpene triepoxide;
organic heteroheptacyclic compound		anti-inflammatory agent;
antineoplastic agent;
immunosuppressive agent
nagilactone c
nagilactone C: norditerpene lactone isolated from leaves of Podocarpus; structure		2.2510
brusatol
brusatol: quassinoid from B. javanica; structure		2.2510triterpenoid
triptolide
[no description available]		6.86240diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
parthenolide
[no description available]		2.2510germacranolide
obacunone
obacunone: from bark of Chinese plant Phellodendron amurense; shortens sleeping time induced in mice by alpha-chloralose-urethane		2.2510limonoid
chlorolissoclimide
chlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson		2.2510
bruceine a
bruceine A: quassinoid which inhibits protein synthesis & DNA synthesis in cells; RN given refers to (11 beta,12 alpha,15 beta)-isomer; structure given in first source		2.2510quassinoid
bruceine b
bruceine B: quassinoid which inhibits protein synthesis & DNA synthesis in cells; structure in first source		2.2510triterpenoid
jolkinolide a
jolkinolide A: isolated from Euphorbia fischeriana		2.2510diterpene lactonemetabolite
jolkinolide b
jolkinolide B: isolated from Euphorbia fischeriana		2.2510diterpene lactonemetabolite
limonin
[no description available]		2.2510epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
sorafenib
[no description available]		2.110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
tripdiolide
tripdiolide: structure		2.2510oxacycle
carboplatin
[no description available]		2.110
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		3.2510resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
thapsigargin
Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.		2.2510butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
IPA-3
IPA-3 : An organic disulfide obtained by oxidative dimerisation of 1-sulfanylnaphthalen-2-ol.		3.2510naphthols;
organic disulfide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
propolin c
propolin C: a PAK1 inhibitor; from Taiwanese propolis; structure in first source. nymphaeol A : A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3' and 4' and a geranyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.		3.25104'-hydroxyflavanones;
tetrahydroxyflavanone		metabolite;
radical scavenger
caffeic acid
trans-caffeic acid : The trans-isomer of caffeic acid.		3.2510caffeic acidgeroprotector;
mouse metabolite
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		3.2510aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone
1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone: structure given in first source; endogenous differentiation-inducing factor; induces stalk-cell differentiation in the cellular slime mold Dictyostelium discoideum		3.2510
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		3.2510carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
bruceantin
[no description available]		2.2510triterpenoid
cucurbitacin i
cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.		3.2510cucurbitacin;
tertiary alpha-hydroxy ketone		antineoplastic agent;
plant metabolite
caffeic acid phenethyl ester
phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.		3.2510alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
andrographolide
[no description available]		2.2510carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
shihulimonin a
shihulimonin A: isolated from Evodia rutaecarpa; structure in first source		2.2510limonoid
dichapetalin a
dichapetalin A: isolated from Dichapetalum; structure in first source		2.2510
artepillin c
artepillin C: RN refers to (E)-isomer		3.2510
ginkgolide b
[no description available]		2.2510
17-hydroxyjolkinolide b
17-hydroxyjolkinolide B: isolated from Euphorbia fischeriana		2.2510diterpene lactonemetabolite
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		2.110oligopeptide
bn 52020
[no description available]		2.2510
nymphaeol c
nymphaeol C: from the leaves of Macaranga tanarius; structure in first source. nymphaeol C : A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3' and 4', a geranyl group at position 2' and a prenyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.		3.25104'-hydroxyflavanones;
tetrahydroxyflavanone		metabolite;
radical scavenger
dichlorolissoclimide
dichlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson		2.2510
ym 155
sepantronium bromide : An organic bromide salt consisting of sepantronium cations and bromide anions. It has been found to selectively inhibit survivin (BIRC5) gene promoter activity and to down-regulate survivin in vitro, so leading to induction of apoptosis.		3.2510organic bromide saltantineoplastic agent;
apoptosis inducer;
survivin suppressant
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.1710
frax486
[no description available]		3.2510
frax597
FRAX597: structure in first source		3.2510
ag-879
AG-879: structure given in first source		3.2510
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		6.74280
ConditionIndicatedRelationship StrengthStudiesTrials
Adenocarcinoma, Basal Cell
[description not available]		02.8130
Cancer of Colon
[description not available]		02.8130
Cancer of Ovary
[description not available]		02.5120
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.8130
Colonic Neoplasms
Tumors or cancer of the COLON.		02.8130
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.5120
Benign Neoplasms
[description not available]		03.5120
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5120
Cancer of Pancreas
[description not available]		05.88200
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		17.88200
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.0120
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		03.0120
Acute Edematous Pancreatitis
[description not available]		03.0610
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		03.0610
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.5720
Anoxemia
[description not available]		02.1510
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.1510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.8430
Carcinoma, Ductal, Pancreatic
[description not available]		02.830
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.830
Disease Exacerbation
[description not available]		02.2110
Acute Myelogenous Leukemia
[description not available]		02.2110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		14.2110
Cancer of Lung
[description not available]		02.7930
Osteogenic Sarcoma
[description not available]		02.0810
Lung Neoplasms
Tumors or cancer of the LUNG.		02.7930
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.0810
Cancer of Liver
[description not available]		03.7130
Liver Neoplasms
Tumors or cancer of the LIVER.		03.7130
Carcinoma, Non-Small Cell Lung
[description not available]		02.5120
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.5120
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.110
Hepatocellular Carcinoma
[description not available]		02.110
Experimental Hepatoma
[description not available]		02.110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.110
Epithelial Ovarian Cancer
[description not available]		02.110
Epithelial Neoplasms
[description not available]		02.110
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.110
HPV Infection
[description not available]		02.110
Carcinoma, Epidermoid
[description not available]		02.110
Cancer of Head
[description not available]		02.110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.110
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.110
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		02.110
B-Cell Chronic Lymphocytic Leukemia
[description not available]		02.1110
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		02.1110
Adenocarcinoma Of Kidney
[description not available]		02.1110
Cancer of Kidney
[description not available]		02.1110
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		02.1110
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.1110
Experimental Neoplasms
[description not available]		02.1310
Androgen-Independent Prostatic Cancer
[description not available]		02.1510
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		02.1510
Cancer of Stomach
[description not available]		02.1510
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.1510